Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 6 49-6, 2004, Pages

  List, James F ^a   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diabetes; Stem cells

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; ZP 10A;

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL PROTECTION; EX VIVO STUDY; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE METABOLISM; HUMAN; HYPOINSULINEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SYNTHESIS; INTESTINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL; STOMACH EMPTYING;

ANIMALS; CELL DIVISION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 2442643059     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00007.2004     Document Type: Short Survey

References (77)

1. Abraham EJ, Leech CA, Lin JC, Zulewski H, and Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143: 3152-3161, 2002.
2. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 3: 365-372, 2003.
3. Ball SG and Barber TM. Molecular development of the pancreatic beta cell: implications for cell replacement therapy. Trends Endocrinol Metab 14: 349-355, 2003.
4. Bonner-Weir S and Sharma A. Pancreatic stem cells. J Pathol 197: 519-526, 2002.
5. Bouwens L. Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Microsc Res Tech 43: 332-336, 1998.
6. Bullock BP, Heller RS, and Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996.
7. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, Di Mario U, and Perfetti R. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29: 347-360, 2002.
8. Buteau J, Foisy S, Joly E, and Prentki M. Glucagon-like peptide I induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132, 2003.
9. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, and Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-induced pancreatic beta-cell proliferation. Diabetes 50: 2237-2243, 2001.
10. Buteau J, Roduit R, Susini S, and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864, 1999.
11. De la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, Yoo SJ, Hao E, Bossie S, and Levine F. Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 15: 476-483, 2001.
12. Docherty K. Growth and development of the islets of Langerhans: implications for the treatment of diabetes mellitus. Curr Opin Pharmacol 1: 641-650, 2001.
13. Doyle ME and Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res 56: 377-399, 2001.
14. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122: 531-544, 2002.
15. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17: 161-171, 2003.
16. Edlund H. Factors controlling pancreatic cell differentiation and function. Diabetologia 44: 1071-1079, 2001.
17. Edvell A and Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 140: 778-783, 1999.
18. Efrat S. Cell replacement therapy for type 1 diabetes. Trends Mol Med 8: 334-339, 2002.
19. Egan JM, Bulotta A, Hui H, and Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19: 115-123, 2003.
20. Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, Bevilacqua G, Buehler MW, and Friess H. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 82: 1481-1492, 2002.
21. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, and Perfetti R. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158, 2003.
22. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-408, 2002.
23. Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijffers R, Kopolovic J, Kaiser N, and Karasik A. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 6: 568-572, 2000.
24. Hoist JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18: 430-441, 2002.
25. Holz GG and Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10: 2471-2483, 2003.
26. Hori Y, Rulifson IC, Tsai BC, Heit JJ, Cahoy JD, and Kim SK. Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc Natl Acad Sci USA 99: 16105-16110, 2002.
27. Hui H, Farilla L, Merkel P, and Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146: 863-869, 2002.
28. Hui H, Nourparvar A, Zhao X, and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444-1455, 2003.
29. Hui H and Perfetti R. Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur J Endocrinol 146: 129-141, 2002.
30. Hui H, Wright C, and Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50: 785-796, 2001.
31. Huotari MA, Miettinen PJ, Palgi J, Koivisto T, Ustinov J, Harari D, Yarden Y, and Otonkoski T. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology 143: 4437-4446, 2002.
32. Huotari MA, Palgi J, and Otonkoski T. Growth factor-mediated proliferation and differentiation of insulin-producing INS-1 and RINm5F cells: identification of betacellulin as a novel beta-cell mitogen. Endocrinology 139: 1494-1499, 1998.
33. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, and Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17: 1575-1580, 2003.
34. Jonsson J, Carlsson L, Edlund T, and Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371: 606-609, 1994.
35. Kieffer TJ and Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
36. Kwon G, Pappan KL, Marshall CA, Schaffer JE, and McDaniel ML. cAMP dose-dependently prevents palmitate-induced apoptosis by both PKA- and cAMP-GEF-dependent pathways in beta-cells. J Biol Chem 279: 8938-8945, 2004.
37. Lam NT and Kieffer TJ. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent. Minerva Endocrinol 27: 79-93, 2002.
38. Lechner A and Habener JF. Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus. Am J Physiol Endocrinol Metab 284: E259-E266, 2003.
39. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003.
40. Lu M, Wheeler MB, Leng XH, and Boyd AE III. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide 1(7-37). Endocrinology 132: 94-100, 1993.
41. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, and McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292: 1389-1394, 2001.
42. Meier J, Gallwitz B, Schmidt W, and Nauck M. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440: 269-270, 2002.
43. Mojsov S, Kopczynski MG, and Habener JF. Both amidated and nonamidated forms of glucagon-like peptide 1 are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008, 1990.
44. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, and Bernier M. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140: 1132-1140, 1999.
45. Nielsen J, Svensson C, Galsgaard E, Moldrup A, and Billestrup N. Beta cell proliferation and growth factors. J Mol Med 77: 62-66, 1999.
46. Orskov C, Rabenhoj L, Wettergren A, Kofod H, and Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
47. Peck AB, Cornelius JG, Schatz DA, and Ramiya VK. Generation of islets of Langerhans from adult pancreatic stem cells. J Hepatobiliary Pancreat Surg 9: 704-709, 2002.
48. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, and Wheeler MB. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47: 1046-1052, 1998.
49. Perfetti R and Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 143: 717-725, 2000.
50. Perfetti R, Zhou J, Doyle ME, and Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141: 4600-4605, 2000.
51. Philippe J, Chick WL, and Habener JF. Multipotential phenotypic expression of genes encoding peptide hormones in rat insulinoma cell lines. J Clin Invest 79: 351-358, 1987.
52. Powers AC, Philippe J, Hermann H, and Habener JF. Sodium butyrate increases glucagon and insulin gene expression by recruiting immunocytochemically negative cells to produce hormone. Diabetes 37: 1405-1410, 1988.
53. Ptasznik A, Beattie GM, Mally MI, Cirulli V, Lopez A, and Hayek A. Phosphatidylinositol 3-kinase is a negative regulator of cellular differentiation. J Cell Biol 137: 1127-1136, 1997.
54. Rachdi L, El Ghazi L, Bernex F, Panthier JJ, Czernichow P, and Scharfmann R. Expression of the receptor tyrosine kinase KIT in mature beta-cells and in the pancreas in development. Diabetes 50: 2021-2028, 2001.
55. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, and Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
56. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238, 2000.
57. Soria B. In-vitro differentiation of pancreatic beta-cells. Differentiation 68: 205-219, 2001.
58. Stoffers DA, Desai BM, DeLeon DD, and Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52: 734-740, 2003.
59. Stoffers DA, Ferrer J, Clarke WL, and Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 17: 138-139, 1997.
60. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, and Egan JM. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748, 2000.
61. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, and Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 15: 106-110, 1997.
62. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, and Knudsen LB. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140: 123-132, 2003.
63. Susini S, Roche E, Prentki M, and Schlegel W. Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J 12: 1173-1182. 1998.
64. Suzuki A, Nakauchi H, and Taniguchi H. Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci USA 100: 5034-5039, 2003.
65. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8645, 1992.
66. Thorkildsen C, Neve S, Larsen BD, Meier E, and Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 307: 490-496, 2003.
67. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51: 1443-1452, 2002.
68. Tourrel C, Bailbe D, Meile MJ, Kergoat M, and Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562-1570, 2001.
69. Valverde I, Villanueva-Penacarrillo M, and Malaisse W. Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 28: 3S85-3S89, 3S108-3S112, 2002.
70. Wang Q and Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273, 2002.
71. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276, 1999.
72. Yada T, Itoh K, and Nakata M. Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3′,5′-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity. Endocrinology 133: 1685-1692, 1993.
73. Yamaoka T. Regeneration therapy of pancreatic beta cells: towards a cure for diabetes? Biochem Biophys Res Commun 296: 1039-1043, 2002.
74. Zhou J, Pineyro MA, Wang X, Doyle ME, and Egan JM. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 192: 304-314, 2002.
75. Zhou J, Wang X, Pineyro MA, and Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48: 2358-2366, 1999.
76. Zhu M, Breslin MB, and Lan MS. Expression of a novel zinc-finger cDNA, 1A-1, is associated with rat AR42J cells differentiation into insulin-positive cells. Pancreas 24: 139-145, 2002.
77. Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Muller B, Vallejo M, Thomas MK, and Habener JF. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50: 521-533, 2001.